Sugi Predict

Sugi Predict / Targets / EPHA6

EPHA6

Ephrin type-A receptor 6 · Q9UF33 · EPHA6 on Sugi Atlas →

2,772 patent compounds predicted against EPHA6, 2,276 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Afatinib Afatinib (SCHEMBL185621) 1.00 2/20
Afatinib Afatinib (SCHEMBL185786) 1.00 2/20
Afatinib Afatinib (SCHEMBL231072) 1.00 2/20
Afatinib Afatinib (SCHEMBL231073) 1.00 2/20
Afatinib Afatinib (SCHEMBL232772) 1.00 2/20
Afatinib Afatinib (SCHEMBL2269415) 1.00 2/20
SCHEMBL1191232 SCHEMBL1191232 0.92 2/20
SCHEMBL1190862 SCHEMBL1190862 0.89 2/20
SCHEMBL1190864 SCHEMBL1190864 0.89 2/20
SCHEMBL1190866 SCHEMBL1190866 0.89 2/20
SCHEMBL1190947 SCHEMBL1190947 0.89 2/20
SCHEMBL1190948 SCHEMBL1190948 0.89 2/20
SCHEMBL1190951 SCHEMBL1190951 0.89 2/20
SCHEMBL1190329 SCHEMBL1190329 0.88 2/20
SCHEMBL1190332 SCHEMBL1190332 0.88 2/20
SCHEMBL1190335 SCHEMBL1190335 0.88 2/20
Afatinib Afatinib (SCHEMBL1942597) 0.86 2/20
Afatinib Afatinib (SCHEMBL1942599) 0.86 2/20
Afatinib Afatinib (SCHEMBL1942600) 0.86 2/20
SCHEMBL1191159 SCHEMBL1191159 0.84 2/20

Clinical trials — most relevant to EPHA6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) PHASE2COMPLETED
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer PHASE1/PHASE2COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) PHASE2ACTIVE_NOT_RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） PHASE2RECRUITING
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC PHASE1/PHASE2UNKNOWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma PHASE1COMPLETED
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors PHASE1COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
The Role of Gene Changes in Brain Tumor Formation and Growth nanCOMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Genetics of Arteriovenous Malformations nanUNKNOWN
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN) nanRECRUITING
Prospective Monocentric Clinical-biological Database nanRECRUITING
Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection nanNOT_YET_RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Hirschsprung Disease Genetic Study nanRECRUITING
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients nanUNKNOWN
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury nanUNKNOWN
Predictive Model for the Occurrence of Cerebral Vasospasm Complicating Subarachnoid Haemorrhage by Combined Analysis of the Kinetics of a Panel of Biomarkers. nanCOMPLETED
Biomarker Research in Inherited Movement Disorders nanRECRUITING
Toxins Removal and Inflammatory State modulAtion During Online Hemodiafiltration: Comparison of Two Different Dialyzers nanUNKNOWN
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a EPHA6 binder may also engage these)

ProteinNameSimilarity
Q62413 — 1.000 Q62413 →
P54758 — 1.000 P54758 →
Q60629 — 1.000 Q60629 →
P54757 — 1.000 P54757 →
EPHA3 Ephrin type-A receptor 3 1.000 landscape →
EPHA5 Ephrin type-A receptor 5 1.000 landscape →
Q07498 — 1.000 Q07498 →
P54755 — 1.000 P54755 →
Q90344 — 1.000 Q90344 →
Q91735 — 0.999 Q91735 →
O42422 — 0.999 O42422 →
Q07497 — 0.999 Q07497 →
Q8CBF3 — 0.999 Q8CBF3 →
Q03145 — 0.999 Q03145 →
Q91571 — 0.999 Q91571 →
O08680 — 0.999 O08680 →
Q91736 — 0.998 Q91736 →
P09759 — 0.998 P09759 →
P29319 — 0.997 P29319 →
P29318 — 0.997 P29318 →
Q91694 — 0.996 Q91694 →
P35546 — 0.996 P35546 →
Q02858 — 0.996 Q02858 →
Q8JFR5 — 0.996 Q8JFR5 →
EPHB2 Ephrin type-B receptor 2 0.996 landscape →
EPHB1 Ephrin type-B receptor 1 0.996 landscape →
Q91845 — 0.996 Q91845 →
Q1KL86 — 0.996 Q1KL86 →
P54759 — 0.995 P54759 →
PTPRM Receptor-type tyrosine-protein phosphatase mu 0.995 landscape →